taipeitimes.com
Drugmakers eye next phase of space research
As the International Space Station approaches retirement, major drugmakers are preparing to conduct commercial pharmaceutical research and manufacturing in low Earth orbit. Executives from pharmaceutical, biotechnology, and space firms are collaborating with regulators to establish guidelines for space-based medicine production, aiming to prove it can be reliable and cost‑effective. Companies such as LambdaVision, Auxilium Biotechnologies, and Merck have already used the ISS to develop retinal implants, bioprinted tissues, and a subcutaneous cancer therapy. The shift toward next‑generation [...]